Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVATURE phenoxodiol plus carboplatin in platinum-resistant or platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
ACTRN12606000471583Phase 3Active, not recruiting
- Sponsor
- MEI Pharma
- Start
- Oct 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Phenoxodiol + carboplatin with Placebo + carboplatin (2 arms). Primary endpoints: Progression-free survival and Drug-associated toxicity and intolerance. Started Oct 2006; status: active, not recruiting.
02
Drugs
idronoxilcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12606000471583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000471583.